OCCIDENT () Overview
- Investor Type
-
Family Office
- Status
-
Active
- Professionals
-
7
- Investments
-
42
- Portfolio
-
17
- Exits
-
11
OCCIDENT () General Information
Company Description
Founded in 2012, OCCIDENT invests in deep tech start-ups with a focus on spin-offs originating from scientific research, thus having a real impact and enabling concrete solutions for different challenges facing society today. As an owner-managed venture capital investor with offices in Munich and Zug, the firm supports start-ups in the life sciences and industrial tech sectors from the seed stage onwards and accompanies their portfolio companies over the long term both financially as well as with their extensive experience. The firm invests its own money and makes decisions.
Business Details
Investor Status
Trade Association
Primary Investor Type
Other Investor Types
Corporate Office
- Klenzestrasse 22
- 80469 Munich
- Germany
OCCIDENT () Investments (42)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Immitra Bio | 21-Jul-2026 | Early Stage VC | Drug Discovery | Pre-Clinical Trials | ||
| Hemotune | 01-Dec-2025 | Therapeutic Devices | Startup | |||
| Tubulis | 15-Oct-2025 | Drug Discovery | Clinical Trials - Phase 2 | |||
| EBAMed | 24-Jan-2025 | Diagnostic Equipment | Generating Revenue | |||
| Lymphatica Medtech | 08-Oct-2024 | Therapeutic Devices | Generating Revenue | |||
| Tubulis | 14-Mar-2024 | Drug Discovery | Clinical Trials - Phase 2 | |||
| Altavo | 01-Feb-2024 | Therapeutic Devices | Generating Revenue | |||
| Chipmetrics | 24-Jan-2024 | Application Specific Semiconductors | Generating Revenue | |||
| ReCatalyst | 12-Jul-2023 | Seed Round | Alternative Energy Equipment | Generating Revenue | ||
| iMusician | 03-May-2023 | PE Growth/Expansion | Media and Information Services (B2B) | Generating Revenue |
OCCIDENT () Exits (11)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Tubulis | 21-May-2026 | Merger/Acquisition | |
| iThera Medical | 11-May-2026 | ||
| Invasight | 24-Oct-2025 | ||
| mk2 Biotechnologies | 03-Feb-2025 | ||
| Lunaphore | 07-Jul-2023 | ||
| Adivo | 07-Jun-2023 | ||
| Versantis | 29-Sep-2022 | ||
| GNA Biosolutions | 05-Feb-2021 | ||
| Cunesoft | 08-Jan-2020 | Buyout/LBO | |
| kooaba | 14-Jan-2014 | Merger/Acquisition |
OCCIDENT () Investments by Industry, Year, and Region
OCCIDENT () Co-Investors (75)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| High-Tech Gründerfonds | 7 |
|
|
||
| Zürcher Kantonalbank |
|
|
|||
| European Innovation Council |
|
|
|||
| Bayern Kapital |
|
|
|||
| CDP Venture Capital (Rome) |
|
|
OCCIDENT () FAQs
-
What is OCCIDENT ()?
Founded in 2012, OCCIDENT invests in deep tech start-ups with a focus on spin-offs originating from scientific research, thus having a real impact and enabling concrete solutions for different challenges facing society today.
-
When was OCCIDENT () founded?
OCCIDENT () was founded in 2012.
-
Where is OCCIDENT () headquartered?
OCCIDENT () is headquartered in Munich, Germany.
-
How many investments has OCCIDENT () made?
OCCIDENT () has made 42 investments.
-
What has OCCIDENT () invested in?
OCCIDENT () has made numerous investments in companies like Immitra Bio, Hemotune, and Tubulis within the Drug Discovery and Therapeutic Devices industries.
-
What has OCCIDENT () invested in recently?
OCCIDENT ()'s latest investment was on 21-Jul-2026 in Immitra Bio, a company within the Drug Discovery industry.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process